Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) (2020)
- Authors
- Cho, Jang Ho; Lim, Sung Hee; An, Ho Jung; Kim, Ki Hwan; Park, Keon Uk; Kang, Eun Joo; Choi, Yoon Hee; Ahn, Mi Sun; Lee, Myung Hee; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Park, Keunchil; Ahn, Myung-Ju
- Issue Date
- Apr-2020
- Publisher
- American Society of Clinical Oncology
- Citation
- Journal of Clinical Oncology, v.38, no.11, pp 1248 - 1248
- Pages
- 1
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of Clinical Oncology
- Volume
- 38
- Number
- 11
- Start Page
- 1248
- End Page
- 1248
- ISSN
- 0732-183X
1527-7755
- Abstract
- The February 10, 2020, article by Cho et al, entitled “Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)” (J Clin Oncol 10.1200/JCO.19.00931), was published with an error. © 2020 American Society of Clinical Oncology. All rights reserved.
- Files in This Item
- There are no files associated with this item.
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Kang, Eun Joo
- Guro Hospital (Department of Medical Oncology and Hematology, Guro Hospital)